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Abstract
Analyses in our diagnostic DNA laboratory include genes involved in autosomal recessive (AR) lysosomal storage disorders
such as glycogenosis type II (Pompe disease) and mucopolysaccharidosis type I (MPSI, Hurler disease). We encountered 4
cases with apparent homozygosity for a disease-causing sequence variant that could be traced to one parent only. In addition,
in a young child with cardiomyopathy, in the absence of other symptoms, a diagnosis of Pompe disease was considered.
Remarkably, he presented with different enzymatic and genotypic features between leukocytes and skin ﬁbroblasts. All cases
were examined with microsatellite markers and SNP genotyping arrays. We identiﬁed one case of total uniparental disomy
(UPD) of chromosome 17 leading to Pompe disease and three cases of segmental uniparental isodisomy (UPiD) causing
Hurler-(4p) or Pompe disease (17q). One Pompe patient with unusual combinations of features was shown to have a mosaic
segmental UPiD of chromosome 17q. The chromosome 17 UPD cases amount to 11% of our diagnostic cohort of
homozygous Pompe patients (plus one case of pseudoheterozygosity) where segregation analysis was possible. We conclude
that inclusion of parental DNA is mandatory for reliable DNA diagnostics. Mild or unusual phenotypes of AR diseases
should alert physicians to the possibility of mosaic segmental UPiD. SNP genotyping arrays are used in diagnostic workup
of patients with developmental delay. Our results show that even small Regions of Homozygosity that include telomeric
areas are worth reporting, regardless of the imprinting status of the chromosome, as they might indicate segmental UPiD.
Introduction
Up to date diagnostics of metabolic disorders includes
mutation analysis of the causative gene. Although enzyme
assays have been considered to be the gold standard for
diagnosis of the symptomatic patient, genotyping is a
requirement for inclusion in enzyme replacement programs
and is a prerequisite for carrier tests in relatives and DNA-
based prenatal diagnosis. For conﬁrmation of allelic segre-
gation, we routinely request parental DNA samples. In this
report, we will refer to those sequence variants known to
cause (Hurler or Pompe) disease in a homozygous or
compound heterozygous state as “pathogenic”.
In recent years, we encountered four cases of apparent
homozygosity for pathogenic variants that could not be
conﬁrmed by parental DNA analyses, as only one of the
parents was a heterozygote. The ﬁrst was a child with
mucopolysaccharidosis type I (Hurler disease, OMIM
607014); three other patients were afﬂicted with glyco-
genosis type II (Pompe disease, OMIM 232300). These four
cases represented 53 homozygous patients with either
Hurler- or Pompe disease where the availability of parental
DNAs allowed segregation analysis.
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Since (partial) gene deletions can generate false homo-
zygosity the relevant gene (IDUA and GAA) regions of the
ﬁrst two patients were interrogated by comparative real
time (quantitative) qPCR. Also, we searched for SNPs in
the amplicons’ primer regions per resequencing.
A special diagnostic case was a young child with car-
diomyopathy (but no muscle weakness), possibly related to
Pompe disease, who was found to have decreased - but not
deﬁcient - acid α-glucosidase activity in leukocytes, but a
deﬁciency in cultured ﬁbroblasts. Onset of cardiomyopathy
within the ﬁrst year without skeletal muscle weakness, with
a sizable (residual) activity of acid α-glucosidase in leuko-
cytes and ﬁbroblasts, represents an uncommon combination
of features when compared with descriptions of the clinical
spectrum of Pompe disease [1, 2]. His GAA genotype
showed apparent heterozygosity for a paternally inherited
pathogenic sequence variant, with some skewing due to an
enhanced paternal contribution and different patterns in
leukocytes and ﬁbroblasts.
Uniparental disomy (UPD) is the inheritance of both
homologues of a pair of chromosomes from one parent
only. Heterodisomy means that both parental homologues
are present, while isodisomy refers to the presence of two
copies of one parental homologue. Segmental UPD is
deﬁned as UPD of a part of one chromosome together with
biparental inheritance of the rest of this pair of chromo-
somes. Problems resulting from UPD are aberrant genomic
imprinting and, in the case of isodisomy, of “homozygosity
of autosomal recessively inherited mutations” [3].
Subsequent analyses of these ﬁve cases with micro-
satellite markers and SNP genotyping arrays showed uni-
parental (iso)disomies. We report four cases of segmental
UPiD and show that a mosaic form of sUPiD can generate a
phenotype with unusual combinations of features. UPiD
may be an underestimated cause of autosomal recessive
disease. Our results bear relevance to genetic counseling of
families with autosomal recessive diseases as well as
diagnostics of patients with mild or unusual phenotypes and
diagnostic workup of patients with developmental disorders
of unknown aetiology using modern screening techniques.
Materials and methods
Patients
For patient A, a clinical diagnosis of mucopolysaccharidosis
type I or type VI was considered at the age of 11 months.
Arylsulfatase B activity in leukocytes was in the normal
range, whereas α-L-iduronidase showed a profound deﬁ-
ciency (0.2 nmoles/17 h/mg, with a normal range of 25–90).
This established the diagnosis of mucopolysaccharidosis
type I (Hurler disease). He was on enzyme replacement
therapy at the age of 13 months and received an allogenic
stem cell transplant at 1 year and 4 months. He has been
free of infections after splenectomy. At 12 years of age, his
cognitive status was at the level of 8 years.
Patient B was born from a consanguineous marriage. Her
parents are ﬁrst cousins. The diagnosis of childhood Pompe
disease was established by the demonstration of deﬁciency
of acid α-glucosidase in cultured ﬁbroblasts when the
patient was 3 years old (0.24 nmoles/h/mg using 4MU
substrate with a normal range of 40–180). Since the parents
opted for PGD (preimplantation genetic diagnosis) in a
subsequent pregnancy mutation analysis of the GAA gene
was requested.
Patient C was hospitalised with respiratory distress
6 weeks and 5 days after birth. The diagnosis of Pompe
disease was established by the demonstration of deﬁciency of
acid α-glucosidase in cultured ﬁbroblasts (0.1 nmoles/min/mg
using 4MU substrate with a normal range of 0.34–2.4 and a
patient range of 0.01–0.3). The patient developed cardio-
myopathy and hepatosplenomegaly. Myozyme enzyme
replacement therapy was started 11 days after admission to
the hospital, but his condition deteriorated and the infant died
with cardiorespiratory arrest 3 weeks after admission.
Patient D, a child of mixed Scandinavian ethnicity, was
diagnosed with Pompe disease at 16 months of age. His
diagnosis was based on clinical symptoms, including
hypertrophic cardiomyopathy and generalized muscle
weakness, and acid α-glucosidase deﬁciency, measured in
isolated lymphocytes. He was treated with Myozyme from
the age of 17 months. DNA was received by our laboratory
(Clinical Genetics, Rotterdam) for mutation analysis when
he was two years of age. There were urgent clinical reasons
to start enzyme replacement therapy immediately after the
biochemical diagnosis had been made and ahead of geno-
typing. Also, the clinical and enzymatic features of the
patient made genetic null variants, which would have been a
contraindication, unlikely; the patient’s positive cross-
reactive immunological material status supported this
decision.
Patient E was born after an uneventful pregnancy. On a
prenatal ultrasound a persistent left superior vena cava was
suspected. Therefore he had a cardiac ultrasound at the age
of 2.5 months. A left ventricular hypertrophy was found,
which later developed into a biventricular cardiac hyper-
trophy. Motor development was normal and the child had
normal strength. As a toddler he does not show symptoms
of muscle weakness or any other clinical symptoms; this
makes him a very unusual case. Because of the infantile
cardiomyopathy a diagnosis of Pompe disease was con-
sidered. The acid α-glucosidase activity in leukocytes was
decreased (26 nmoles/h/mg) but clearly above the activity in
known Pompe patients (range normal controls 40–250,
patients 0–10). However, in cultured ﬁbroblasts, the activity
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was 8.1 nmoles/h/mg using 4MU substrate (with a normal
range of 45–180 and a patient range of 0–20).
DNA isolation and mutation analysis
DNA was extracted from blood using Magnetic Separation
Module 1 from Chemagen (Baesweiler, Germany). Routine
mutation analysis of the IDUA and GAA genes was done by
sequencing of the coding exons and intron exon boundaries,
i.e. exons 1–14 (IDUA; NM_000203.3 (GRCh37/hg19)),
exon numbering as in https://databases.lovd.nl/shared/
refseq/IDUA_NM_000203.3_table.html and Kwak et al.
[4], and 2–20 (GAA; NM_000152.3 (GRCh37/hg19)), exon
numbering as in https://databases.lovd.nl/shared/refseq/
GAA_NM_000152.3_table.html and Kroos et al [5].
(In addition, the (relatively frequent) deletion of exon 18 of
GAA was tested with a separate deletion speciﬁc PCR.)
Primers were designed using standard software (Primer3,
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi);
sequences available on request. PCR products were puriﬁed
with ExoSap-it (USB, Cleveland, Ohio, USA) and
sequenced using the Big Dye Terminator kit according to
the supplier’s instructions (Applied Biosystems, Foster
City, California, USA). Sequence reaction products were
puriﬁed with Performa DTR V3–96 well short plates (Edge
BioSystems, Gaithersburg, Maryland, USA) and analysed
using an ABI 3730 XL analyzer (Applied Biosystems) and
SeqScape (Applied Biosystems) or SeqPilot software (JSI
medical systems GmbH).
In vitro functional testing of a GAA missense variant
using site directed mutagenesis was performed as published
by Kroos et al. [5]. Data on the variants and the patients
were submitted to www.lovd.nl/IDUA and www.lovd.nl/
GAA. Patients A-E were registered as #00183080,
#00183081, #00183082, #00183083 and #00183084,
respectively.
Identity testing
The AmpFlSTR® Identiﬁler® PCR Ampliﬁcation Kit was
used to verify the origin of patients’ and parental samples.
qPCR analysis - Copy number variation detection
Two real-time PCR techniques were used to detect a pos-
sible deletion in IDUA and GAA (http://www.eurogentec.
com/8233Discover+our+new+qPCR+guide.html). First,
TaqMan Probe assays were designed using Primer Express
2.0 (Applied Biosystems) and performed on an ABI 7500,
using qPCR low ROX MasterMix Plus (Eurogentec). For
IDUA exons 1–14 were tested and for the GAA gene exon 3,
8, 13 and 18. Subsequently, results were veriﬁed with
SYBR green assays on an ABI 7900 using MESA GREEN
qPCR MasterMix Plus for SYBR assay Low Rox (Euro-
gentec) for exon 2 of the IDUA gene and exon 13 of the
GAA gene using the TaqMan assay outer primers.
Marker analysis
Microsatellite markers for chromosome 4 (n= 8) and
chromosome 17 (n= 15) were selected from the GB AB
Map (ABI PRISM Linkage Mapping Set Version 2, Panel
Guide and the UCSC hg19 genome browser (http://genome.
ucsc.edu/cgi-bin/hgGateway). The VIC or FAM labelled
PCR products were run on the ABI 3730 XL. The markers
are summarised in Table 1.
SNP microarray analysis
For patients A and B, SNP array analysis was performed
with Affymetrix SNP6.0 arrays according to the manu-
facturer’s protocol (Santa Clara, CA, USA) as described [6].
(Affymetrix is now part of ThermoFisher Scientiﬁc, Wal-
tham, MA, USA). DNA trio analysis of patient C and
parents was done on the 300 K Illumina (San Diego, CA,
USA) HumanCytoSNP-12 BeadChip platform [7, 8] and
trioanalyses of patients D and E and their parents were done
Table 1 Markers on chromosome 4 and 17 used for this study
Marker Chromosome Start pos. (hg19) End pos. (hg19)
D4S412/a 4 3380692 3381012
D4S2935/b 4 6560881 6561231
D4S403/c 4 13750828 13751166
D4S405/d 4 40352512 40352915
D4S1592/e 4 57681811 57682157
D4S1572/f 4 103769921 103770290
D4S415/g 4 178711416 178711101
D4S1535/h 4 185235750 185236098
D17S831/i 17 1910400 1910767
D17S1852/j 17 10515501 10515829
D17S921/k 17 14260599 14260928
D17S1857/l 17 16415217 16415593
D17S1824/m 17 26659952 26660227
D17S798/n 17 31289812 31290190
D17S927/o 17 35006344 35006731
D17S1868/p 17 47184746 47185087
D17S944/q 17 61436174 61436545
D17S785/r 17 74431300 74431581
D17S1790/s 17 75297293 75297627
D17S802/t 17 76234526 76234797
D17S836/u 17 77299839 77300058
D17S784/v 17 77802121 77802424
D17S928/w 17 80252839 80253140
/a etc refers to the position in Fig. 2.
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on the Illumina InﬁniumCytoSNP-850K BeadChip platform
[8, 9]. These platforms had (consecutively) become part of
our standard clinical laboratory procedure. A cascade of
algorithms was applied for copy number analysis and gen-
otyping, including Genome Studio (Illumina), GTC (Affy-
metrix) and Nexus CopyNumber™ (Biodiscovery, El
Segundo, CA, USA). Analysis of LOH (Loss of Hetero-
zygosity) was based on B-allele frequency calculation
(BAF), the B-allele representing the minor non-reference
allele. Expected values for BAF are 0 for AA, 0.5 for AB
and 1 for BB, meaning ΔBAF represents estimated devia-
tion from the expected AB value.
Results
Mutation analysis of patients and parents
After DNA sequencing, the Hurler disease patient A, pre-
sented as homozygous for the founder (nonsense) variant
c.208 C > T, p.(Gln70*) in exon 2 of the IDUA gene
(chromosome 4p16.3) known to occur in patients with
Hurler disease in a homozygous or compound heterozygous
state. Subsequently, both parents were tested and the mother
was heterozygous for c.208 C > T, p.(Gln70*); the father,
however, tested negative. Pompe patient B appeared to be
homozygous for the novel nonsense variant c.1853G >A,
p.(Trp618*) in exon 13 of the GAA gene (chromosome
17q25.2-q25.3). Both parents were tested, with mother
heterozygous and father negative for c.1853G >A,
p.(Trp618*). In both families paternity was conﬁrmed.
Repeated sequencing of the patients’ DNA using new sets
of primers outside the originally ampliﬁed fragments did not
reveal any SNPs that might have compromised the detection
of the paternal allele in the previous tests. Two more
patients were encountered, both with sequence alterations in
exon 5 of the GAA gene: Pompe patient C, with apparent
homozygosity for the founder pathogenic missense variant
c.925 G > A, p.(Gly309Arg), and Pompe patient D, whose
DNA showed a homozygous pattern for the novel missense
change c.871 C > T, p.(Leu291Phe), of which the clinical
relevance was unknown. The functional signiﬁcance of this
change was studied using site directed mutagenesis.
The resulting classiﬁcation was a ‘pathogenic potentially
severe to slightly less severe’ variant. Also in these cases
only the patients’ mothers carried the variant. Paternity was
conﬁrmed. Patient E, who had hypertrophic cardiomyo-
pathy, but no muscle weakness, had decreased (but not
deﬁcient) acid α-glucosidase activity in leukocytes, but a
deﬁciency in cultured ﬁbroblasts. GAA genotyping was
done on DNA from leukocytes and from ﬁbroblasts. In both
DNA samples a pattern with a normal (maternal) and a
mutant (paternal) allele was observed. It concerned the
founder pathogenic missense variant c.925 G > A, p.
(Gly309Arg). Each of the patterns was skewed, in the sense
that the (mutant) A peak was higher than the G (Fig. 1),
which was more pronounced in the ﬁbroblast DNA.
Comparative qPCR with TaqMan Probe and SYBR
green assays for copy number quantiﬁcation
We continued the analyses of patients A and B using qPCR
with TaqMan Probe and SYBR green assays. This was to
explore the possibility that the apparently homozygous
patterns of sequence variants in these patients and the
apparently wild type patterns in their fathers would repre-
sent exon deletions on the paternal alleles [10]. Assays were
designed for exon 2 of the IDUA gene containing the
apparently homozygous variant of patient A; exons 1 and
3–14 served as control exons. Assays of the GAA gene
concerned exon 13 containing the apparently homozygous
variant of patient B; exons 3, 8 and 18 served as control
exons. All assays gave normal results for patients A and B
and their parents (results not shown). This indicates that
heterozygous partial gene deletions were not the cause of
the observed discrepancies in these patients’ and paternal
DNAs.
Analyses of microsatellite markers and microarrays
The parental contributions to the chromosomal areas
involved were further investigated. For the IDUA gene, 8
microsatellite markers on chromosome 4 were tested,
designated a-h in Fig. 2 and listed in Table 1. Of these,
D4S412/a, D4S2935/b, D4S403/c and D4S405/d were
located proximal to IDUA on the short arm and D4S1592/e,
D4S1572/f, D4S415/g and D4S1535/h on the long arm of
the chromosome. Four markers (D4S405/d, D4S1592/e,
D4S1572/f and D4S1535/h) showed biparental inheritance
(paternal contributions) in proband A’s DNA, three markers
(D4S412/a, D4S2935/b and D4S415/g) were not informa-
tive, but for D4S403/c at 4p16.1 patient A showed absence
of a paternal allele. Together with the apparently homo-
zygous maternal sequence variant this suggested segmental
uniparental isodisomy (sUPiD). To examine this further,
SNP genotyping array analyses were performed.
For patient A, investigated on Affymetrix SNP6.0, the
GTC software showed one region of homozygosity with a
size of 18Mb on chromosome 4pter (Fig. 2A; supplemen-
tary ﬁgure S1A and S1B). The homozygous, copy neutral,
region comprised the IDUA gene and marker D4S403,
which showed only a maternal contribution in the marker
analysis.
For the cases involving the GAA gene (chromosome
17q25.2–25.3), 15 markers were tested including 6 markers
at chromosome 17q25 (Table 1; designated i-w in Fig. 2).
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Of the latter, D17S785/r, D17S1790/s, D17S802/t,
D17S836/u and D17S784/v were proximal to GAA and
D17S928/w was distal to the gene (Fig. 2B–E). The
remaining markers i-q covered 17p13.3 through 17q23.3. In
DNA of proband B, the distal marker D17S1928/w showed
one of the maternal alleles and no paternal allele. Markers
D17S836/u, D17S802/t and D17S785/r at chromosome
17q25 showed biparental inheritance, as did the other
informative markers at 17q11.2–17p13.3. Using array ana-
lysis (Affymetrix SNP6.0), patient B showed one 3.5 Mb
region of homozygosity on chromosome 17qter (Fig. 2B;
supplementary ﬁgure S2A and S2B). This copy neutral
region included the GAA gene and one of the marker loci,
i.e. D17S928/w, that showed only the maternal allele in the
marker analysis. The remaining chromosomal regions con-
sisted of biparental contributions as evidenced by both
normal array results and the informative markers. In DNA
of patient C, markers D17S928/w, D17S784/v, D17S802/t
and D17S785/r located on either side of the gene at
17q25 showed patterns in agreement with maternal UPiD
(Fig. 2C, and supplementary ﬁgure S3). Seven markers
throughout the remaining part of the chromosome showed
biparental inheritance. Patient C was further analysed using
the Illumina CytoSNP-12 platform. One region of (copy
neutral) homozygosity of 8 Mb was observed encompassing
the distal marker D17S928/w and GAA and ending just
centromeric to the informative marker D17S785/r. The
remaining chromosomal patterns were of biparental origin.
We conclude that patients A, B and C were all cases of
maternal sUPiD. For patient D (Fig. 2D; supplementary
ﬁgure S4) all markers at 17q25 showed patterns in agree-
ment with maternal UPD, of which D17S928/w, D17S802/t,
D17S1790/s and D17S785/r were informative for UPiD.
D17S1868/p at 17q21.32, however, showed maternal het-
erodisomy (UPhD), as did D17S831/i at 17p13.3, with 2
markers in between showing isodisomic patterns. Array
analyses (Illumina CytoSNP-850K) showed allelic imbal-
ance throughout the chromosome with ROH blocks at 17q25
and 17q12–17p13.1 coinciding with the regions of UPiD
indicated by the markers, whereas the remaining areas were
in agreement with maternal UPhD as they did not show
ROH and lacked paternal contributions. These results indi-
cate the presence of maternal whole chromosome UPD, with
alternating regions of homozygosity and heterozygosity,
consistent with a meiosis I error resulting in maternal UPhD.
Array analysis (Illumina CytoSNP-850K) was the most
informative tool for patient E. Allelic imbalance of a large
region (39.5 Mb) was detected, compatible with a segmental
mosaic ROH (Fig. 2E; supplementary ﬁgure S5), as evi-
denced by an estimated 0.17 BAF deviation. His
DNA showed biparental marker patterns throughout the
Father
925
G T C G G C W C A C R G G G T G T T C C
Proband
(Leukocytes)
925
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Proband
(Fibroblasts)
925
G T C G GC T C A C R G G G T G T T C C
Mother
G T C G
925
G C W C A C G G G G T G T T C C
Mutation Analysis in Family E
Fig. 1 Sequence analysis of exon 5 of the GAA gene. Both parents are
heterozygous for c.921A > T, a silent change (p.Ala307= ), the pro-
band shows a homozygous T pattern. Position 925 is indicated by
arrows. The father is heterozygous for c.925G >A; p.(Gly309Arg), a
known pathogenic variant, mother has wild type sequence. The pro-
band shows skewed, pseudoheterozygous, patterns in leukocytes and
(brieﬂy) cultured ﬁbroblasts, with the highest mutant peak in the
ﬁbroblasts
Segmental and total uniparental isodisomy (UPiD) as a disease mechanism in autosomal recessive. . . 923
chromosome. However, in agreement with the results of the
mutation analysis, at the 17q25 region 5 of the markers had
enhanced peaks of one paternal allele. We conclude that this
case represents a mosaic paternal sUPiD.
Discussion
Using microsatellite markers and SNP microarrays we
identiﬁed 5 cases of UPD in patients with autosomal
recessive lysosomal storage diseases, 4 of which were
maternal in origin and 1 was paternal. It concerned one case
of Hurler disease and four with Pompe disease including
one case with an unusual combination of features. Four of
these cases were traced when apparent homozygosity for a
Hurler- or Pompe disease-causing variant was found in the
patients and only the mothers proved to be carriers. Con-
ﬁrmation of biological parenthood was done by separate
assay and/or was inherent in the results of the (comparative)
analyses. Exon deletions and SNPs in primer areas had been
excluded in patients A and B. For the patients we encoun-
tered more recently, microarray analyses became tools at an
earlier stage of diagnostic work up, which enabled direct
allelic quantiﬁcation. Only one case (patient D) showed
wUPD, with alternating regions of UPiD and UPhD
reﬂecting a meiosis I origin [11]. The remaining cases
represented postzygotic events resulting in segmental
UPiDs, one of them in a visibly mosaic form and of paternal
origin (patient E). This ﬁnding was particularly relevant for
the diagnosis of patient E. He had presented with infantile
cardiomyopathy, but has no muscle weakness, also as a
toddler, which is an unusual combination. He had a
decreased acid α-glucosidase activity in leukocytes that was
above the range of known Pompe disease patients. How-
ever, the enzyme activity in cultured ﬁbroblasts was within
the patient range. Genotyping showed normal patterns in the
mother’s DNA and heterozygosity for a known pathogenic
variant in the father. In the patient both leukocytes and
ﬁbroblasts showed skewed heterozygous pattern with a
more pronounced (paternal) variant allele than the (mater-
nal) normal allele in the ﬁbroblast DNA (Fig. 1). This may
reﬂect the difference in enzyme activity between both tis-
sues and strongly indicated mosaic sUPiD. Marker analyses
on DNA from leukocytes and ﬁbroblasts of this patient were
less informative than in the other - non-mosaic - cases,
where absence of parental contribution can be seen. Five
markers did show enhanced peaks of one paternal allele, but
the difference between the two tissues was less obvious.
SNP genotyping array analysis on leukocyte DNA was
clearly consistent with mosaicism, as 2 cell populations
were visible (Fig. 2E; supplementary ﬁgure S5), while copy
number neutral [12]. One may speculate that the resulting
enzyme activity in skeletal muscle was above the threshold
for clinical expression at the present age of the patient,
whereas the activity in the heart was not sufﬁcient to pre-
vent cardiomyopathy.
Fig. 2 Graphic images of chromosome 4 (patient A) and chromosome
17 (patients B–E), based on the results of microsatellite marker and
SNP genotyping array analyses. The microsatellite marker loci are
listed in Table 1. The colours of the bars indicate: Gray – biparental
contributions / absence of UPD. Purple – region of UPiD. Yellow –
region of UPhD. Green - allelic imbalance, interpreted as admixture of
biparental UPiD cell populations. Supplementary ﬁgures 1–5 contain
array data
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The estimates of the occurrence of (germline) UPD vary
considerably. The most widely cited prevalence of UPD-
for-any-chromosome is 1/3500 births [13]. Using exome
sequencing and microarray analysis King et al. [14] detec-
ted six cases of UPD, one of them segmental, in 1057
previously investigated but undiagnosed children with
developmental disorders, which would represent a sig-
niﬁcant enrichment. Segmental UPiD has been attributed to
postzygotic somatic recombination between maternal and
paternal homologues or chromosomal breakage and repair
using the homologous chromosome as a template [3, 15].
There is a tenfold difference between the reported numbers
of wUPD (n= 3653) and sUPD (n= 363) [16]. It is con-
ceivable that the number of reported sUPD will increase due
to a more widespread application of high resolution ana-
lyses of the genome. The vast majority of reported sUPiD to
date concerned paternal sUPiD of chromosome 11p causing
Beckwith Wiedemann syndrome. Recently, mosaic sUPiD
and progressive clonal selection have been identiﬁed as a
common mechanism leading to late onset ß-thalassemia
major [17].
After Sanger sequencing of 40 different AR genes in
their clinical service, Landsverk et al. [18] reported 75 cases
of apparent homozygosity with available parental DNAs. In
9/75 (12%) cases parental carrier status could not be con-
ﬁrmed. Four cases were attributed to deletions or allele drop
out due to private SNPs in primer regions. In two cases
UPiD was identiﬁed, one case each of segmental and
complete UPD. However, UPiD was not unlikely in the
three unresolved, but only partially analysed cases, which
would bring the maximum percentage of UPD cases to
6.7%. In our diagnostic laboratory, Pompe disease is the
most frequently tested lysosomal storage disease. In our
ﬁles (1995-October 2015) were 272 index cases -of 32
nationalities- conﬁrmed by GAA genotyping, 64 of whom
were apparently homozygous for a pathogenic variant. In 35
of these cases both parents could be examined and we
identiﬁed one case of total maternal UPD and two cases of
segmental maternal UPiD including the GAA gene at
17q25.3 without evidence of mosaicism. In addition, one
case of skewed heterozygosity was shown to represent
mosaic segmental paternal UPiD. Hence, we saw four cases
(11%) of UPD among 36 cases where segregation could be
tested. This percentage of cases that ‘did not inherit the
mutation from each parent’ is similar to Landverk’s data,
but we identiﬁed UPDs only and no cases with deletions or
allele drop out.
The patients with sUPDs at 17q came from 4 different
countries and their disomic regions were all different in size
varying from 3.5 to 39.5 Mb, the latter covering about three
quarters of chromosome 17q. This illustrates that the cen-
tromeric boundaries of the sUPDs are not conﬁned to spe-
ciﬁc regions.
The number of Hurler/Scheie cases in our lab is lower
than the number of Pompe cases. We tested 74 index
patients, of whom 29 were homozygous for a pathogenic
IDUA variant. We identiﬁed the case of sUPiD described in
this report out of a total of 18 homozygous patients where
both parents could be tested.
Since we argued that the occurrence of UPD may be
underestimated due to unavailability of parental DNA, we
compared the results with a cohort of cystic ﬁbrosis (CF)
patients tested in our lab with both parental DNAs available.
In 120 homozygous cases segregation was consistent with
AR inheritance. The occurrence of human disease resulting
from UPD was ﬁrst demonstrated already in 1988 in a CF
patient with maternal UPiD for chromosome 7 by Spence
et al. [19]. However, we did not identify any case of UPiD
in a CF cohort of 120 patients. In the literature, we could
ﬁnd no more than 9 CF patients reported with (total and
segmental) UPiD [20, 21]. This number seems low for a
genetic disease with a mean calculated incidence of 1:3500
in Europe, based on data from 26 regional and national CF
newborn screening programs [22]. Some underreporting in
the literature cannot be excluded. Also, large numbers of
patients may be needed for CF, where the relative con-
tribution of UPD to the incidence of the disease may be
lower due to the high carrier frequency. We propose to do a
survey among diagnostic laboratories about their UPD cases
to collect sufﬁcient data for statistical analysis and investi-
gate the frequency of UPD as a cause of AR disease.
Our results underline the clinical relevance of testing
parental DNAs in the course of a routine diagnostic workup
for DNA diagnostics of autosomal recessive diseases even
when the parents are consanguineous (patient B). It is of
direct importance to the parents in the ﬁrst place, as a
recessive disease caused by this mechanism has a negligible
recurrence risk compared with the 25% that is conferred by
biparental carriership.
Awareness of this genetic mechanism in diagnostic
laboratories will speed up genotyping, when apparently
conﬂicting results are found between the results of patients
and parents. This is of particular relevance for patients with
lysosomal storage diseases as a growing number of enzyme
replacement programs become available where genotyping
is a requirement for inclusion.
The case with the mosaic segmental UPD is very rele-
vant with respect to cases with mild phenotypes (resem-
bling those) of known recessive diseases. In the case of
autosomal recessive diseases de novo sequence changes
affecting gene (product) function appear to occur extremely
rarely. Hence possible mosaicism can easily be overlooked
or even ignored. When, however, genotypic or metabolic/
enzymatic features are observed to vary according to the
tissue analysed, mosaicism for segmental UPD must be
considered.
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Our observations also bear relevance for the protocol
used for diagnostic workup for patients with developmental
delay and intellectual disability that often involves SNP
genotyping arrays at an early stage. It is important not only
to check for genes involved in autosomal recessive diseases
in “whole chromosome ROH” or repeated ROHs on one
chromosome with interspersed heterozygosity indicating
(whole chromosome) UPD. Even relative small ROHs
(< 10Mb) that include telomeric regions might indicate
segmental UPD (e.g. patients B and C). We recommend that
diagnostic laboratories report terminal ROHs regardless of
size or the imprinting status of the chromosome.
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